Top 10 Articles on Morningstar

Most popular with Morningstar.co.uk readers this week: Should you invest in Neil Woodford's new fund and the 10 stocks bought by top fund managers

Emma Wall 9 June, 2014 | 12:55PM
Facebook Twitter LinkedIn

What are investors reading? Here are the top 10 articles and videos from Morningstar.co.uk over, as chosen by fellow Morningstar.co.uk readers over the past week.

Should You Buy Neil Woodford's Fund?

ASK THE EXPERT: Legendary UK equity income fund manager Neil Woodford launches his eponymous fund this month. But should you buy it?

10 Stocks Bought by Top Fund Managers

The equity pickings continue to get slimmer for a proven group of top fund managers as the market continues to trade around its all-time high

5 Highest Yielding Investment Trusts

THE INCOME INVESTOR: Looking for income? These investment trusts have a portfolio of high yielding international stocks and an inflation beating dividend

Tesco Shares 'Attractive' Despite Drop in Sales

Tesco noted that about 50% its underperformance relative to the market was due to its decision to reduce promotions by two thirds, compounded by intense competition

Fund Basics

A guide to fund investing for beginners...and those more experienced investors who need a re-cap

Best Interest Rate on Cash

Want to get the best possible rate of return on cash? Don't need instant access to your savings? Then these are the savings accounts for you

Which UK Companies are Undervalued?

THE VALUE INVESTOR: Which sectors are the most over-priced when it comes to UK equities? And which stock market is undervalued and which look overheated?

Where to Invest When All Assets are Expensive

Think bonds are pricey and equities are at the top of their valuations? Schroder's Marcus Brookes outlines where value hunters can find options in an expensive market

5 Value Stocks the Fund Managers Own

THE VALUE INVESTOR: We have cut out the middle man and reveal the equities the value fund managers are holding in their portfolios for long-term growth

Astra Shares Worth £35

Despite rejecting Pfizer's takeover bid and a declining competitive advantage, analysts have upped AstraZeneca's valuation thanks to key product developments

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Emma Wall  is former Senior International Editor for Morningstar

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures